THE LACTIgA PLATFORM.

Lactiga is advancing the development of secretory IgA (sIgA)-based biologics based on its essential role in mucosal immune defense. sIgA binds to pathogens, preventing their attachment to epithelial cells, neutralizes toxins, and regulates the microbiota by selectively binding to and controlling specific microbial populations. By reducing pro-inflammatory cytokines, sIgA modulates the immune response and supports immune homeostasis.

Lactiga’s therapeutic approach is designed to treat immune deficiencies and other conditions characterized by compromised mucosal immunity. With significant progress in research and development, Lactiga is positioned to advance these biologics into clinical evaluation and commercialization.

TRANSFORMING TREATMENT ACROSS DISEASE STATES

  • Lactiga’s lead asset, LCTG-001, is a nasal sIgA spray that normalizes nasal concentrations of secretory IgA in patients with primary immunodeficiency diseases such as CVID, sIgAD, and XLA. These rare conditions can lead to frequent respiratory infections and irreversible lung damage that even antibiotics fail to treat. By restoring sIgA levels in these patients using Lactiga’s innovative nasal spray, we can enhance their immune function and modulation to protect them against further infection and damage. 

  • LCTG-003 is intended to be an oral capsulated sIgA replacement therapy for IBD and other GI disorders. The dysregulated immune response that characterizes these disorders is likely triggered by a loss of immune tolerance to bacterial antigens. As such, restoring sIgA levels can also help restore immune balance and relieve symptoms in these disease states. 

  • Lactiga’s secretory IgA (sIgA) therapy strengthens the body's defenses where it matters most — the respiratory tract. By delivering protective antibodies directly to the airways, our sIgA therapy can help prevent infections and reduce inflammation in conditions like non-CF bronchiectasis, COPD, and chronic lung allograft dysfunction (CLAD), offering a new layer of protection for people with chronic lung diseases.